What is the best taper schedule for a 71‑year‑old patient taking buspirone 5 mg twice daily, trazodone 50 mg twice daily, mirtazapine 15 mg at bedtime, and lorazepam 0.25 mg twice daily, and what medication should be added for agitation related to dementia?

Immediate Priority: Taper Lorazepam First and Add Low-Dose Atypical Antipsychotic

Your 71-year-old patient is on a dangerously complex polypharmacy regimen that requires urgent simplification, with lorazepam posing the highest immediate risk and requiring priority tapering, while a low-dose atypical antipsychotic should be added specifically for dementia-related agitation. 1, 2, 3

Critical Context: Why This Regimen is Problematic

This patient is on four psychotropic medications with overlapping sedative effects, creating substantial fall risk, cognitive impairment, and paradoxical agitation risk. The guidelines are clear: benzodiazepines in elderly dementia patients carry excessive risk 2, with regular use leading to tolerance, addiction, depression, and cognitive impairment, plus paradoxical agitation in ~10% of patients 1. The 2025 geriatric emergency guidelines found midazolam had 53% adverse event rates, and benzodiazepines generally pose "excessive risk" in older adults 2.

---

Step 1: Lorazepam Taper (HIGHEST PRIORITY)

Lorazepam must be tapered using hyperbolic (proportionate) reductions, not linear reductions, to minimize withdrawal symptoms.

Taper Schedule for Lorazepam 0.25 mg BID (0.5 mg total daily):

• Week 1-2: Reduce to 0.25 mg in AM, 0.125 mg in PM (0.375 mg/day total)
• Week 3-4: Reduce to 0.125 mg BID (0.25 mg/day total)
• Week 5-6: Reduce to 0.125 mg in AM only (0.125 mg/day)
• Week 7-8: Reduce to 0.125 mg every other day
• Week 9-10: Reduce to 0.0625 mg (1/16th tablet) daily
• Week 11-12: Discontinue

Critical principles 4, 5:

• Use hyperbolic (proportionate) reductions of approximately 10-25% of the current dose every 1-2 weeks, NOT linear reductions
• The final doses must be very small (as low as 0.0625 mg or less) because the last step to zero represents the same pharmacological change as earlier reductions
• If withdrawal symptoms emerge (anxiety, insomnia, tremor, agitation), pause the taper or increase back to the previous tolerated dose 6, 7
• Consider liquid formulation or compounded preparations for precise small-dose reductions 5
• Withdrawal symptoms can be severe and protracted after long-term use 8, 4

---

Step 2: Add Atypical Antipsychotic for Dementia-Related Agitation

Start risperidone 0.25 mg at bedtime OR quetiapine 12.5 mg twice daily for agitation control while tapering other medications. 1

Rationale:

• Atypical antipsychotics are specifically recommended for "control of problematic delusions, hallucinations, severe psychomotor agitation, and combativeness" in dementia 1
• Risperidone: Initial dose 0.25 mg/day at bedtime; maximum 2-3 mg/day. Current research supports LOW dosages; extrapyramidal symptoms may occur at ≥2 mg/day 1
• Quetiapine: Initial dose 12.5 mg BID; maximum 200 mg BID. More sedating; beware transient orthostasis 1
• Olanzapine (2.5 mg at bedtime) is another option, generally well-tolerated 1

Critical Warnings:

• Use the lowest effective dose for the shortest time necessary 3, 9
• Benefits are "at best small" in clinical trials, but can minimize violence risk, reduce distress, and improve quality of life 3
• Monitor for extrapyramidal symptoms, falls, sedation, and metabolic effects
• Reassess need every 3-6 months with empirical taper attempts 10

---

Step 3: Simplify Antidepressant Regimen (After Lorazepam Taper Complete)

This patient is on THREE antidepressants (trazodone, mirtazapine, buspirone), which is excessive and likely contributing to sedation and fall risk.

Recommended Approach:

Keep mirtazapine 15 mg at bedtime as the primary antidepressant (addresses both depression and sleep) and taper the others:

Taper Trazodone (currently 50 mg BID = 100 mg/day):

• Week 1-2: Reduce to 50 mg in AM, 25 mg in PM (75 mg/day)
• Week 3-4: Reduce to 25 mg BID (50 mg/day)
• Week 5-6: Reduce to 25 mg at bedtime only
• Week 7-8: Reduce to 25 mg every other day
• Week 9-10: Discontinue

Note: Trazodone IS recommended as a mood-stabilizing/antiagitation drug in dementia (initial 25 mg/day, max 200-400 mg/day) 1, but this patient's dose is modest and the polypharmacy burden outweighs benefit. If agitation persists despite the atypical antipsychotic, consider keeping low-dose trazodone (25-50 mg/day) instead of discontinuing.

Taper Buspirone (currently 5 mg BID = 10 mg/day):

• Week 1-2: Reduce to 5 mg daily (morning)
• Week 3-4: Reduce to 2.5 mg daily
• Week 5-6: Discontinue

Rationale: Buspirone is "useful only in patients with mild to moderate agitation" and "may take 2-4 weeks to become effective" 1. At this low dose, it's unlikely providing significant benefit and adds to pill burden. One small study showed buspirone may aid benzodiazepine withdrawal 11, but evidence is limited.

Mirtazapine Considerations:

• Current dose (15 mg at bedtime) is appropriate starting dose 12
• Gradual taper required if discontinuing to avoid withdrawal reactions 12
• If discontinuing mirtazapine later, reduce by 25% every 1-2 weeks (15 mg → 11.25 mg → 7.5 mg → 3.75 mg → stop) 13
• Avoid alternate-day dosing as this risks severe withdrawal effects 13

---

Timeline Summary

Months 1-3: Focus on Lorazepam Taper + Add Antipsychotic

• Week 1: Start risperidone 0.25 mg HS (or quetiapine 12.5 mg BID)
• Weeks 1-12: Complete lorazepam taper using hyperbolic reductions
• Continue trazodone, mirtazapine, buspirone unchanged during this period

Months 4-5: Taper Trazodone and Buspirone

• After lorazepam fully discontinued and patient stable for 2-4 weeks
• Taper trazodone over 10 weeks
• Taper buspirone over 6 weeks (can overlap with trazodone taper)

Month 6+: Reassess

• Patient should be on: Mirtazapine 15 mg HS + Risperidone 0.25-0.5 mg HS (or quetiapine equivalent)
• Monitor agitation control
• Attempt empirical taper of antipsychotic after 3-6 months if agitation resolved 10

---

Critical Monitoring and Pitfalls

During Lorazepam Taper:

• Withdrawal symptoms: Anxiety, insomnia, tremor, agitation, seizures (rare at this dose)
• Rebound agitation: May worsen temporarily; this is where the atypical antipsychotic provides coverage
• Cognitive function: Should IMPROVE as benzodiazepine discontinued

During Antipsychotic Use:

• Falls risk: Orthostatic hypotension, sedation, gait instability
• Extrapyramidal symptoms: Rigidity, tremor, akathisia (especially risperidone >1 mg/day)
• Metabolic effects: Weight gain, glucose dysregulation (especially olanzapine)
• Mortality risk: FDA black box warning for increased mortality in dementia patients 14

General Principles:

• Never use linear dose reductions for benzodiazepines or antidepressants 13, 4
• Avoid anticholinergic medications (diphenhydramine, benztropine) which worsen cognition 1, 14
• Document indication clearly for all medications 15
• Proactive medication reviews every 3-6 months 14, 15

---

Alternative Considerations

If agitation is severe and risperidone/quetiapine insufficient, consider:

• Divalproex sodium (Depakote): 125 mg BID, titrate to therapeutic level (40-90 mcg/mL); generally better tolerated than carbamazepine 1
• Citalopram: Specifically studied for agitation in Alzheimer's disease 9
• Avoid typical antipsychotics (haloperidol) due to 50% risk of tardive dyskinesia after 2 years in elderly 1

The key is systematic simplification with one medication change at a time, prioritizing the most dangerous agent (lorazepam) first, while providing adequate coverage for agitation with an evidence-based agent (low-dose atypical antipsychotic).